Eyepoint Completes Enrollment In Pivotal Phase 3 Lugano Trial Of Duravy For Treatment Of Wet Age-Related Macular Degeneration
May 27 (Reuters) - EyePoint Pharmaceuticals Inc EYPT.O:
EYEPOINT COMPLETES ENROLLMENT IN PIVOTAL PHASE 3 LUGANO TRIAL OF DURAVYU™ FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION
EYEPOINT PHARMACEUTICALS INC - LUCIA PHASE 3 TRIAL EXPECTED TO COMPLETE ENROLLMENT IN 3Q 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.